rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    INCY
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Incyte wins EU nod for Povofortay in hidradenitis suppurativa
      Nov 17Seeking AlphaINCY
      Incyte at UBS Global Biopharma Conference 2026: growth beyond Jakafi
      Nov 17Investing.comINCYUBS
      Jefferies reiterates Hold on Incyte stock with $115 price target
      Nov 17Investing.comINCY
      Incyte at Jefferies Global Healthcare Conference: pipeline bets grow
      Nov 17Investing.comINCYJEF
      Incyte cancels planned Phase 3 ovarian cancer study for CDK2 inhibitor
      Nov 14Investing.comINCY
      How Incyte Trial And New Cancer Data Will Impact Natera Stock
      Nov 13Yahoo FinanceINCYNTRA
      Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains
      Nov 11MarketWatchINCY
      Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030
      Nov 11Yahoo FinanceINCY
      Natera and Incyte partner on Phase II colorectal cancer trial
      Nov 11Yahoo FinanceINCYNTRA
      Natera, Incyte partner on colorectal cancer trial using MRD test
      Nov 10Investing.comINCYNTRA
      Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
      Nov 10Yahoo FinanceINCYNTRA
      Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Novavax (NVAX)

      Detailed price information for Novavax Inc (NVAX-Q) from The Globe and Mail including charting and trades.

      Nov 7The Globe and MailINCYNVAX
      Incyte Corp principal accounting officer sells $72,565 of stock
      Nov 6Investing.comINCY
      Incyte Corp. stock underperforms Thursday when compared to competitors
      Nov 5MarketWatchINCY
      $1000 Invested In Incyte 20 Years Ago Would Be Worth This Much Today
      Nov 5BenzingaINCY
      Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
      Nov 4Yahoo FinanceINCY
      What Does Incyte (INCY) First Patient Dosing Mean For Its Colorectal Cancer Pipeline?
      Oct 31Yahoo FinanceINCY
      Incyte Corp. stock outperforms competitors on strong trading day
      Oct 30MarketWatchINCY
      Incyte upgraded at Oppenheimer on growth beyond Jakafi

      Oppenheimer upgrades Incyte, citing growth beyond Jakafi exclusivity loss, strong Opzelura sales, and pipeline upside. Read more here.

      Oct 30Seeking AlphaINCYOPY
      Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte. Intel, Reddit, Rivian Automotive, and More
      Oct 30Yahoo FinanceDASHHONHONAINCYINTCRIVNBBYBSXGEV
      Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
      Oct 30BenzingaINCY
      H.C. Wainwright reiterates Incyte stock rating on cancer trial progress
      Oct 30Investing.comINCY
      Oppenheimer upgrades Incyte stock rating on growth outlook
      Oct 30Investing.comINCY
      Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap (NASDAQ:INCY)
      Oct 30Seeking AlphaINCY
      Incyte Corporation Q3 2026 Earnings Call Summary
      Oct 30Yahoo FinanceINCY
      Incyte Corp (INCY) Q3 2026 Earnings Call Highlights: Revenue Up 14% as Core Business Surges 30% ...
      Oct 29Yahoo FinanceINCY
      What Incyte (INCY) Said on Its Q3 Earnings Call

      Incyte (NASDAQ:INCY) reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The company also raised its full-year sales outlook for OPZELURA, hematology and oncol

      Oct 29Yahoo FinanceINCY
      Incyte Q3 2026 slides: core business surges 37% as pipeline expands
      Oct 29Investing.comINCY
      Earnings call transcript: Incyte tops revenue forecasts in Q3 2026, shares slip
      Oct 29Investing.comINCY
      Incyte Q3 2026 Earnings Call Transcript
      Oct 29BenzingaINCY
      Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say
      Oct 29Yahoo FinanceINCY
      Incyte’s (NASDAQ:INCY) Q3 2026 sales beat estimates but full-year sales guidance misses expectations significantly

      Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 14% year on year to $1.56 billion. On the other hand, the company’s full-year revenue guidance of $5.26 billion at the midpoint came in 11.3% below analysts’ consensus estimates. Its non-GAAP loss of $3.60 per share was 6.9% above analysts’ consensus estimates.

      Oct 29Yahoo FinanceINCY
      Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates

      Incyte (INCY) delivered earnings and revenue surprises of +9.77% and +5.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Oct 29Yahoo FinanceINCY
      Incyte earnings missed by $0.07, revenue topped estimates
      Oct 29Investing.comINCY
      Incyte: Q3 Earnings Snapshot
      Oct 29Yahoo FinanceINCY
      Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
      Oct 29Yahoo FinanceINCY
      Incyte earnings up next: Analysts eye loss amid pipeline gains
      Oct 28Investing.comINCY
      Incyte (INCY) reports Q3: everything you need to know ahead of earnings
      Oct 28Yahoo FinanceINCY
      Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
      Oct 28Yahoo FinanceADAGINCY
      Incyte Corp. stock outperforms competitors on strong trading day
      Oct 27MarketWatchINCY
      Stifel reiterates Incyte stock rating on cancer drug data
      Oct 27Investing.comINCY
      BMO reiterates Incyte stock rating on solid tumor progress
      Oct 27Investing.comINCY
      Incyte stock price target maintained at $152 by H.C. Wainwright on cancer drug data
      Oct 27Investing.comINCY
      Oppenheimer reiterates Incyte stock rating on pipeline progress
      Oct 27Investing.comINCY
      Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs - Slideshow
      Oct 27Seeking AlphaINCY
      Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Erasca (ERAS) and Incyte (INCY)

      Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

      Oct 27The Globe and MailERASINCYMRK
      Incyte Highlights Promising Early Data for ’890 and ’734 in GI Cancers
      Oct 27Yahoo FinanceINCY
      Incyte Corporation (INCY) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow (NASDAQ:INCY) 2026-10-26
      Oct 26Seeking AlphaINCY
      Incyte Corp. stock underperforms Monday when compared to competitors
      Oct 26MarketWatchINCY
      Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
      Oct 26Yahoo FinanceGMABINCY

      This is the newest page. Registered accounts read further back.